Amgen receives positive CHMP opinion to extend indication of Kyprolis to treat relapsed multiple myeloma

Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. http://processandproduction.pharmaceutical-business-review.com/news/amgen-receives-positive-chmp-opinion-to-extend-indication-of-kyprolis-to-treat-relapsed-multiple-myeloma-310516-4908548